CurifyLabs
An automated 3D printing platform designed for personalized medicine, enabling pharmacies and hospitals to manufacture tailored drug dosages on-site.
- CEO / Founder
- Charlotta Topelius
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- €17.6M
- Latest Round
- Series A (Springvest)
- Key Investors
- Lifeline Ventures (Seed lead), Springvest (Series A lead), Pharmacy Pension Fund (Apteekkien Eläkekassa), Business Finland (grants and €1M deep tech loan in Series A), European Innovation Council (EIC Accelerator €2.5M grant)
Technology & Products
Key Products
PharmaPrinter Aurum: Next-generation 3D printer for pharmaceutical compounding that makes compounding up to 9x faster than manual processes. Features integrated quality control, compact design, and supports multiple dosage forms including troches, films, gel tablets, suppositories, and capsules. Part of the Compounding System Solution (CSS) combining proprietary software, GMP-manufactured excipients, and advanced 3D printing technology.
Technological Advantage
Utilizes a proprietary 'Tailored Dose' technology that combines hardware, software, and validated ink formulations, allowing for the production of complex drug combinations and specific release profiles that are impossible with traditional tableting.
Differentiation
Value Proposition
Replaces manual, error-prone compounding processes with an automated 'mini-factory' approach, ensuring precise dosage customization, improved patient safety, and reduced pharmaceutical waste.
How They Differentiate
Proprietary GMP-grade Pharma Inks and an end-to-end automated 'MiniLab' system (CSS) that integrates hardware, software, and validated formulations for on-site pharmacy and hospital use.
Market & Competition
Target Customers
Compounding pharmacies, hospital pharmacies, veterinary clinics, and pharmaceutical research institutions.
Industry Verticals
["Healthcare","Pharmaceuticals","Veterinary Medicine","Personalized Medicine"]
Competitors
Aprecia Pharmaceuticals; FabRx; CraftHealth
Growth & Milestones
Growth Metrics
Tripled company revenue in 2024 and reached a milestone of 26,000 tablets produced by customers across 8 European countries.
Major Milestones
["Launched the next-generation PharmaPrinter Aurum in January 2026","Secured €6.7M Series A funding led by Springvest in May 2025","Partnered with APL Sweden to improve pediatric medicine administration in September 2024","Launched the first-ever GMP-manufactured Pharma Inks for 3D printing in October 2023","Winner of the 2025 'Productive Idea' (Tuottava Idea) award by JCI Finland"]
Notable Customers
Apotek Produktion & Laboratorier (APL) - Sweden; The Woodlands Compounding Pharmacy - USA; iGalenici - Italy; Johannes Gutenberg University Mainz Hospital Pharmacy